Cyclerion Therapeutics (CYCN) Shares Outstanding (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Shares Outstanding (Entity) of $3.9 million for Q4 2025, up 44.84% year-over-year from $2.7 million in Q4 2024, and up 2.91% quarter-over-quarter from $3.8 million in Q3 2025.
Cyclerion Therapeutics (CYCN) Shares Outstanding (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Shares Outstanding (Entity) history runs 8 years deep, the most recent figure standing at $3.9 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 44.84% year-over-year to $3.9 million; the TTM figure through Dec 2025 stood at $3.9 million (up 44.84% YoY), while the FY2025 annual figure was $3.9 million, up 44.84% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $3.9 million, up from $3.8 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $3.9 million in Q4 2025, with the low at $2176.0 in Q1 2023.
- The 5-year median for Shares Outstanding (Entity) is $2.4 million (2023), against an average of $2.4 million.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) plunged 99.9% in 2023, then surged 124444.85% in 2024.
- Cyclerion Therapeutics' Shares Outstanding (Entity) stood at $2.2 million in 2021, then increased by 0.25% to $2.2 million in 2022, then rose by 21.56% to $2.6 million in 2023, then increased by 2.46% to $2.7 million in 2024, then soared by 44.84% to $3.9 million in 2025.
- Business Quant data shows CYCN's Shares Outstanding (Entity) at $3.9 million in Q4 2025, $3.8 million in Q3 2025, and $3.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | 3.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.23 Mn |
| Sep 30, 2025 | 3.23 Mn |
| Jun 30, 2025 | 3.07 Mn |
| Mar 31, 2025 | 2.56 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Sep 30, 2024 | 2.53 Mn |
| Jun 30, 2024 | 2.51 Mn |
| Mar 31, 2024 | 2.49 Mn |
| Dec 31, 2023 | 2.34 Mn |
| Sep 30, 2023 | 2.44 Mn |
| Jun 30, 2023 | 2.28 Mn |
| Mar 31, 2023 | 2,176.00 |
| Dec 31, 2022 | 2.17 Mn |
| Sep 30, 2022 | 2.17 Mn |
| Jun 30, 2022 | 2.17 Mn |
| Mar 31, 2022 | 2.17 Mn |
| Dec 31, 2021 | 1.96 Mn |
| Sep 30, 2021 | 2.16 Mn |
| Jun 30, 2021 | 1.79 Mn |
| Mar 31, 2021 | 1.70 Mn |